Drug Trial Radar · NCT00360555
Uptitration Trial of Flibanserin Versus Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder
Last checked: Nov 20, 2026Latest source record: Jun 27, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,584
Actual
Start
Jul 2006
Primary completion
Mar 2008
Study completion Mar 2008
Sponsor
- Lead sponsor
- Sprout Pharmaceuticals, IncIndustry
- Sponsor type
- Industry
- First posted
- Aug 4, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is designed to assess the safety and efficacy of flibanserin in the treatment of premenopausal women with Hypoactive Sexual Desire Disorder (HSDD) that meets standard diagnostic criteria. Efficacy for flibanserin will be assessed vs. a parallel placebo group.
Conditions
- Sexual Dysfunctions, Psychological
Interventions
flibanserinDrug
flibanserin 25 mg b.i.d
flibanserin 50mgDrug
flibanserin 50mg qhs/b.i.d.
flibanserin 100mgDrug
flibanserin 50 mg b.i.d/100mg qhs
placeboDrug
placebo comparator
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in the Frequency of Satisfying Sexual Events (SSE) as Recorded in the eDiary.Time frame: baseline to 28 weeks
- Change From Baseline in the Monthly Sum of Responses Recorded in the eDiary to the Daily Desire Question.Time frame: baseline to 24 weeks
Locations
77 sites in 2 countries. Site status is shown where the registry gives one.
511.75.01015 Boehringer Ingelheim Investigational Site
Birmingham, Alabama
511.75.01028 Boehringer Ingelheim Investigational Site
Mobile, Alabama
511.75.01051 Boehringer Ingelheim Investigational Site
Phoenix, Arizona
511.75.01063 Boehringer Ingelheim Investigational Site
Little Rock, Arkansas
511.75.01017 Boehringer Ingelheim Investigational Site
Berkeley, California
511.75.01014 Boehringer Ingelheim Investigational Site
Encinitas, California
511.75.01042 Boehringer Ingelheim Investigational Site
Fair Oaks, California
511.75.01022 Boehringer Ingelheim Investigational Site
Irvine, California
511.75.01005 Boehringer Ingelheim Investigational Site
La Jolla, California
511.75.01053 Boehringer Ingelheim Investigational Site
Sacremento, California
511.75.01045 Boehringer Ingelheim Investigational Site
San Diego, California
511.75.01065 Boehringer Ingelheim Investigational Site
Aurora, Colorado
511.75.01003 Boehringer Ingelheim Investigational Site
Englewood, Colorado
511.75.01030 Boehringer Ingelheim Investigational Site
Washington D.C., District of Columbia
511.75.01066 Boehringer Ingelheim Investigational Site
Coral Gables, Florida
511.75.01040 Boehringer Ingelheim Investigational Site
Fort Meyers, Florida
511.75.01001 Boehringer Ingelheim Investigational Site
Gainesville, Florida
511.75.01062 Boehringer Ingelheim Investigational Site
Hollywood, Florida
511.75.01032 Boehringer Ingelheim Investigational Site
Ocala, Florida
511.75.01047 Boehringer Ingelheim Investigational Site
Orlando, Florida
511.75.01073 Boehringer Ingelheim Investigational Site
Palm Bay, Florida
511.75.01035 Boehringer Ingelheim Investigational Site
Sarasota, Florida
511.75.01010 Boehringer Ingelheim Investigational Site
South Miami, Florida
511.75.01041 Boehringer Ingelheim Investigational Site
St. Petersburg, Florida
511.75.01033 Boehringer Ingelheim Investigational Site
Tampa, Florida
511.75.01002 Boehringer Ingelheim Investigational Site
West Palm Beach, Florida
511.75.01006 Boehringer Ingelheim Investigational Site
Sandy Springs, Georgia
511.75.01023 Boehringer Ingelheim Investigational Site
Chicago, Illinois
511.75.01031 Boehringer Ingelheim Investigational Site
Fort Wayne, Indiana
511.75.01050 Boehringer Ingelheim Investigational Site
Lafayette, Louisiana
511.75.01043 Boehringer Ingelheim Investigational Site
Bingham Farms, Michigan
511.75.01025 Boehringer Ingelheim Investigational Site
Chaska, Minnesota
511.75.01024 Boehringer Ingelheim Investigational Site
Chesterfield, Missouri
511.75.01009 Boehringer Ingelheim Investigational Site
Kansas City, Missouri
511.75.01060 Boehringer Ingelheim Investigational Site
Las Vegas, Nevada
511.75.01004 Boehringer Ingelheim Investigational Site
New Brunswick, New Jersey
511.75.01037 Boehringer Ingelheim Investigational Site
Chapel Hill, North Carolina
511.75.01054 Boehringer Ingelheim Investigational Site
Winston-Salem, North Carolina
511.75.01069 Boehringer Ingelheim Investigational Site
Beachwood, Ohio
511.75.01012 Boehringer Ingelheim Investigational Site
Cincinnati, Ohio
Showing 40 of 77 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.